Company Filing History:
2 out of 79 
2 out of 441 
Years Active: 2024-2025
Title: Ayaka Yatsu: Innovator in Antibody Development
Introduction
Ayaka Yatsu is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of bispecific antibodies. With a total of 2 patents to her name, Yatsu is recognized for her innovative approaches to cancer treatment.
Latest Patents
Yatsu's latest patents focus on bispecific antibodies that serve as anti-tumor agents. One of her notable inventions describes an antibody that comprises a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, and a heavy chain CDRH3 consisting of SEQ ID NO: 56. Additionally, it includes a light chain CDRL1 that can either consist of SEQ ID NO: 57 or an amino acid sequence derived from SEQ ID NO: 57, with specific modifications at amino acids 7 and 8. The patent also details a light chain CDRL2 consisting of SEQ ID NO: 58 and a light chain CDRL3 consisting of SEQ ID NO: 59 or a modified version of it.
Career Highlights
Throughout her career, Ayaka Yatsu has worked with esteemed institutions such as Mie University and Daiichi Sankyo Company, Limited. Her work has been pivotal in advancing the understanding and application of bispecific antibodies in therapeutic settings.
Collaborations
Yatsu has collaborated with notable colleagues, including Hiroshi Shiku and Yasushi Akahori. These partnerships have contributed to her innovative research and development efforts.
Conclusion
Ayaka Yatsu stands out as a leading inventor in the field of biotechnology, particularly in the development of bispecific antibodies for cancer treatment. Her contributions continue to influence the landscape of medical research and innovation.